KalVista Pharmaceuticals ... (KALV)
11.11
-0.04 (-0.40%)
At close: Apr 02, 2025, 3:59 PM
11.02
-0.75%
After-hours: Apr 02, 2025, 07:56 PM EDT
-0.40% (1D)
| Bid | 10.49 |
| Market Cap | 552.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -3.77 |
| PE Ratio (ttm) | -2.95 |
| Forward PE | -3.19 |
| Analyst | Buy |
| Ask | 11.61 |
| Volume | 762,989 |
| Avg. Volume (20D) | 462,621 |
| Open | 11.18 |
| Previous Close | 11.15 |
| Day's Range | 10.84 - 11.50 |
| 52-Week Range | 7.30 - 15.50 |
| Beta | 0.76 |
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 9, 2015
Employees 150
Stock Exchange NASDAQ
Ticker Symbol KALV
Website https://www.kalvista.com
Analyst Forecast
According to 8 analyst ratings, the average rating for KALV stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 98.11% from the latest price.
Stock Forecasts3 months ago
+8.28%
KalVista Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
4 months ago
+9.61%
KalVista Pharmaceuticals shares are trading higher. The company announced a share offering and private placement.
